Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
LB Pharmaceuticals Inc Common Stock(LBRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LBRX
11/13/2026: LBRX (4-star) is a STRONG-BUY. BUY for 4 days. Simulated Profits (-4.29%). Updated daily EoD!
LB Pharmaceuticals is a clinical-stage biotechnology firm focused on developing small-molecule therapies for neuropsychiatric conditions, with LB-102 serving as its lead candidate for acute schizophrenia. The company’s primary strength lies in its focused R&D pipeline and successful recent Nasdaq listing, which provided the capital necessary for its pivotal Phase 3 trial. Its primary investment story centers on the potential for regulatory approval of LB-102, which could disrupt the established antipsychotic treatment market. Risks include clinical trial binary outcomes, reliance on a single lead asset, and competition from large pharmaceutical incumbents. The stock is a suitable consideration for high-growth-oriented investors, with clinical data readouts serving as key developments to monitor.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-growth potential linked directly to the success of its late-stage clinical programs. |
| Momentum investor | Strong fit while signal remains positive | The stock has experienced significant volatility and price movement, making it attractive to momentum-focused strategies. |
| Value investor | Weak fit | As a pre-revenue clinical-stage firm, there is no earnings-based valuation to support a value-investing thesis. |
| Dividend investor | Weak fit | The company is in an intensive investment phase and does not pay dividends. |
| Low-risk investor | Weak fit | The binary nature of clinical trial outcomes and biotech volatility make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechs often experience extreme price swings tied to study results and regulatory news. |
| Valuation risk | Medium / high | The stock price is driven by speculative potential, which can lead to rapid corrections if clinical milestones are missed. |
| Competition risk (CNS market) | Medium / high | The neuropsychiatric space is crowded with well-funded competitors with existing distribution and clinical advantages. |
| Business quality | Medium | While the science is advanced, the company lacks a commercial-stage product and proven revenue generation. |
| Dividend income | Low / none | The company prioritizes aggressive reinvestment in R&D over cash returns to shareholders. |
| Execution risk | High | Success depends entirely on the successful completion of the Phase 3 NOVA-2 trial and future FDA approval. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.37B USD | Price to earnings Ratio - | 1Y Target Price 58 |
Price to earnings Ratio - | 1Y Target Price 58 | ||
Volume (30-day avg) 410.3K shares | Beta - | 52 Weeks Range 15.13 - 50.16 | Updated Date 11/13/2026 |
52 Weeks Range 15.13 - 50.16 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 78.16% | Avg. Invested days 41 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Research & Development | Currently primarily R&D activities focused on the LB-102 therapeutic candidate. | The company does not currently sell products; it generates value for shareholders through successful progress in clinical trials. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 975.86M | Price to Sales(TTM) - |
Enterprise Value 975.86M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 32.36M | Shares Floating 26.56M |
Shares Outstanding 32.36M | Shares Floating 26.56M | ||
Percent Insiders 0.24 | Percent Institutions 106.79 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.